Blood test could help predict skin cancer's return

December 5, 2017, Cancer Research UK

Cancer Research UK scientists have discovered that testing skin cancer patients' blood for tumour DNA could help predict the chances of an aggressive cancer returning.

Published in the Annals of Oncology today, the findings could pave the way to identifying patients who are most at risk of their disease returning, and who might benefit from new immunotherapy treatments.

Led by researchers based at the Cancer Research UK Manchester Institute and The Christie NHS Foundation Trust, scientists studied blood samples taken after surgery from 161 patients with stage 2 and 3 melanoma. They then looked for faults in two genes that are linked to 70% of melanoma skin cancers - BRAF and NRAS.

After five years, 33% of patients who had a positive blood for faults in either of the two genes were alive, compared to 65% of those who did not.

The results also revealed that skin was much more likely to return within a year of surgery in patients who had faults in either of the two genes.

Each year around 15,400 people in the UK are diagnosed with malignant melanoma. And while survival has doubled in the last 40 years, around 2,500 people die from the disease every year in the UK.

Professor Richard Marais, lead researcher and director of the Cancer Research UK Manchester Institute, based at the University of Manchester, said: "For some patients with advanced melanoma, their cancer will eventually return. We have no accurate tests to predict who these patients will be, so our findings are really encouraging. If we can use this tumour DNA test to accurately predict if cancer is going to come back, then it could help doctors decide which patients could benefit from new immunotherapies. These treatments can then reduce the risk of the cancer spreading. The next step is to run a trial where patients have regular blood tests after their initial treatment has finished in order to test this approach."

Professor Karen Vousden, Cancer Research UK's chief scientist, said: "Being able to develop an early warning system that will predict if a cancer will return could make a real difference to . Research like this shows that for some cancers, there may be ingenious solutions - such as a test. If follow up research shows that this test can be used to inform treatment decisions and improve outlook, it could be a game-changer in our ability to deal with advanced ."

Explore further: Blood test may give early warning of skin cancer relapse

More information: Lee, R. J., Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma. Annals of Oncology (2017)

Related Stories

Blood test may give early warning of skin cancer relapse

March 7, 2016
A blood test may be able to sound early warning bells that patients with advanced melanoma skin cancer are relapsing, according to a study published in the journal Cancer Discovery today (Monday).

Blood test could predict best treatment for lung cancer

November 21, 2016
A blood test could predict how well small-cell lung cancer (SCLC) patients will respond to treatment, according to new research published in Nature Medicine today (Monday).

Scientists learn more about rare skin cancer that killed Bob Marley

August 20, 2014
Cancer Research UK scientists have discovered that acral melanomas – the rare type of skin cancer that caused reggae musician Bob Marley's death – are genetically distinct from other more common types of skin cancer, ...

Diabetes treatment doubles skin cancer drug's effectiveness

April 2, 2012
Combining the experimental drug Avastin (bevacizumab) with the diabetes drug Metformin almost doubles its ability to reduce skin cancer growth, according to a study in Cancer Discovery.

Simple test predicts return of bladder cancer

July 7, 2017
Scientists have devised a simple test for an earlier and more accurate warning of returning bladder cancer than existing methods, according to research published in the British Journal of Cancer today.

Testing for immune 'hotspots' can predict risk that breast cancer will return

August 4, 2017
Scientists have developed a new test that can pick out women at high risk of relapsing from breast cancer within 10 years of diagnosis.

Recommended for you

Researchers artificially generate immune cells integral to creating cancer vaccines

August 14, 2018
For the first time, Mount Sinai researchers have identified a way to make large numbers of immune cells that can help prevent cancer reoccurrence, according to a study published in August in Cell Reports.

Chemicals found in vegetables prevent colon cancer in mice

August 14, 2018
Chemicals produced by vegetables such as kale, cabbage and broccoli could help to maintain a healthy gut and prevent colon cancer, a new study from the Francis Crick Institute shows.

Lymphatic vessels unexpectedly promote the spread of cancer metastases

August 14, 2018
Lymphatic vessels actively contribute to the spread of cancer metastases from various organs. This unexpected realisation is the result of a joint study by researchers from ETH Zurich and the University Hospital Zurich as ...

Ovarian cancer genetics unravelled

August 14, 2018
Patterns of genetic mutation in ovarian cancer are helping make sense of the disease, and could be used to personalise treatment in future.

Researchers uncover a major new vulnerability of childhood leukemia

August 14, 2018
Childhood leukemia is a diagnosis that no family ever wants to endure. While the treatment of most types of leukemia has improved steadily over the years, a few specific types remain very difficult to treat. One of these ...

Stress hormone is key factor in failure of immune system to prevent leukemia

August 14, 2018
The human stress hormone cortisol has been identified by scientists at the University of Kent as a key factor when the immune system fails to prevent leukemia taking hold.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.